Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH ready for eMDR testing

This article was originally published in The Gray Sheet

Executive Summary

FDA's device center announces it is ready to start testing electronic submissions of medical device reports under its eMDR program. In the works for several years, the program aims to improve the center's ability to detect more critical adverse event reports among the more than 200,000 adverse event submissions it receives annually. Most of the submissions currently are sent in by fax, and must be typed in manually by data entry contractors. The project is one component of the center's expansive postmarket "transformation" initiative (1"The Gray Sheet" Feb. 20, 2006, p. 12). CDRH is accepting eMDR submissions from anyone who would like to participate. The program eventually will be mandatory as FDA moves to go completely electronic...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel